Overview
India has validated Truenat HR-HPV-Plus, its first indigenous point-of-care test for cervical cancer screening. Developed by Molbio Diagnostics, the test meets WHO international standards. It detects eight high-risk HPV types responsible for 95% of cervical cancers. India records 127,000 new cases and 80,000 deaths annually from this preventable disease.
A Silent Killer That Can Be Stopped
Cervical cancer is a disease that kills nearly 80,000 women in India every year. That is about 200 women every day. Most of these deaths happen because the cancer is detected too late. The main cause of cervical cancer is a common virus called Human Papillomavirus, or HPV. For years, the only reliable tests for HPV were expensive and imported. They required sophisticated laboratories and trained technicians. Women in small towns and villages had little access. Now, that has changed. India has developed and validated its own HPV test. It is called Truenat HR-HPV-Plus . It is affordable, easy to use, and works at the point-of-care – meaning in a local clinic, not a faraway lab.
What is HPV and Why Does It Cause Cancer?
HPV stands for Human Papillomavirus. It is a group of more than 100 related viruses. Some types are low-risk and cause warts. Others are high-risk and can cause cancer. Persistent infection with high-risk HPV types is the primary cause of cervical cancer. The cervix is the lower, narrow part of the uterus. When high-risk HPV infects the cells of the cervix, it can slowly turn them into cancer cells over many years. But this process is slow – usually 10 to 15 years. That gives a big window for screening. If we can detect the virus early, we can treat the precancerous cells and prevent cancer altogether.
The Burden of Cervical Cancer in India
India carries a heavy burden. According to recent data, India records about 127,000 new cervical cancer cases and 80,000 deaths each year. This is nearly one-fifth of the global burden. Many of these women are young mothers, breadwinners, and caregivers. Their deaths leave families shattered. The tragedy is that cervical cancer is highly preventable. Two tools exist: vaccination (to prevent HPV infection) and screening (to detect HPV or precancerous changes). India has launched a national HPV vaccination campaign for girls. But for women above 30 who may already have been exposed, screening is the only hope. And until now, screening was not accessible to most.
Truenat HR-HPV-Plus: The Indian Solution
Truenat HR-HPV-Plus is a molecular diagnostic test developed by Molbio Diagnostics , a company based in Goa. It is designed to run on the Truenat platform – a portable, battery-operated device already used across India for testing tuberculosis, COVID-19, and other infectious diseases. The test detects eight high-risk HPV types that are responsible for about 95% of all cervical cancers. It is a point-of-care test, meaning it can be done in a primary health centre or a district hospital. The patient does not need to travel to a big city lab. The result is available in about an hour.
Rigorous Validation: Meeting International Standards
India did not just release the test without proof. A thorough validation study was conducted. The study involved top institutions: AIIMS New Delhi , institutes of the Indian Council of Medical Research (ICMR) , and the World Health Organization’s International Agency for Research on Cancer (IARC) in Lyon, France. The results were published in the International Journal of Cancer , a respected peer-reviewed journal.
The study used 1,159 cervical samples to evaluate four Indian-developed HPV tests. The tests were compared against gold-standard reference tests used by WHO and IARC. Among all four, Truenat HR-HPV-Plus was the only one to fully satisfy the international validation criteria . It showed high sensitivity (correctly identifying those with the virus) and high specificity (correctly identifying those without). It also met strict reproducibility standards, meaning different laboratories got the same results.
The Truenat Advantage: Already in the Field
One of the biggest strengths of Truenat HR-HPV-Plus is that it runs on a platform already familiar to Indian healthcare workers. The Truenat system is used in over 1,500 districts for TB testing. Health workers already know how to operate the machine, collect samples, and interpret results. This means no expensive new equipment and no lengthy retraining. The test can be rolled out quickly across the country. This is a huge advantage over imported tests that require new machines and specialised labs.
National Context and Government Support
The validation of Truenat HR-HPV-Plus did not happen in a vacuum. It received support from DBT-BIRAC under the Grand Challenges India initiative. BIRAC (Biotechnology Industry Research Assistance Council) is a government agency that promotes innovation in biotechnology. The official announcement of the validation was made in New Delhi on 23 April 2025 . The event was attended by Dr. Jitendra Singh , Minister of State (Independent Charge) for Science and Technology. He emphasised that the goal is to make screening affordable and accessible, especially for women in smaller towns.
India’s approach to cervical cancer is two-pronged: vaccination for prevention in young girls, and screening for early detection in women above 30. The validation of Truenat HR-HPV-Plus gives a powerful new tool for the screening arm.
A Human Touch: What This Means for a Rural Woman
Imagine a 35-year-old woman named Sunita. She lives in a small village in Uttar Pradesh. She has three children. She has never heard of HPV. She has never been screened for cervical cancer. One day, a female health worker visits her village with a portable Truenat device. She explains that a simple test can detect a virus that causes cancer. Sunita agrees. The health worker takes a sample. Within an hour, she knows she has a high-risk HPV infection. She is referred to a district hospital for further examination. Because the infection was caught early, precancerous cells are removed. Sunita goes home healthy. She will live to see her children grow up. This is not a dream. It is now possible because of an Indian-made test.
The Road Ahead
The validation is a major milestone. But the real work begins now. The test must be manufactured at scale, distributed widely, and integrated into India’s public health system. Training programmes for health workers will need to expand. Awareness campaigns will need to educate women about the importance of screening. The government will need to allocate funds. But the foundation is solid. India now has an indigenous, affordable, and validated HPV test that can reach the last mile.
Conclusion
The validation of Truenat HR-HPV-Plus is a proud moment for Indian science and public health. It shows that India can innovate, not just import. It offers a realistic path to reducing the terrible burden of cervical cancer in the country. With vaccination and screening working together, India can aim to eliminate cervical cancer as a public health problem. The test is ready. The platform is in place. Now, it is time to save lives.
Exam-Focused Points
-
Test name: Truenat HR-HPV-Plus.
-
Developer: Molbio Diagnostics, Goa.
-
Purpose: Cervical cancer screening by detecting high-risk HPV types.
-
HPV full form: Human Papillomavirus.
-
HPV types detected: Eight high-risk types causing ~95% of cervical cancers.
-
Cervical cancer burden in India: 127,000 new cases, 80,000 deaths annually.
-
Validation institutions: AIIMS New Delhi, ICMR institutes, WHO’s IARC (France).
-
Validation study published in: International Journal of Cancer.
-
Samples used: 1,159 cervical samples.
-
Outcome: First indigenous point-of-care HPV test to fully satisfy international validation criteria.
-
Supporting initiative: Grand Challenges India (DBT-BIRAC).
-
Truenat platform already used for: TB, COVID-19, other infectious diseases.
-
Key government figure: Dr. Jitendra Singh (MoS Science & Technology).
-
Official announcement date: 23 April 2025.
-
Screening target group: Women above 30 years.
Frequently Asked Questions (FAQ)
Q1: What is Truenat HR-HPV-Plus?
A: It is an Indian-made, point-of-care molecular test that detects high-risk types of HPV that cause cervical cancer.
Q2: How accurate is the test?
A: In a validation study with 1,159 samples, it fully satisfied international WHO and IARC criteria for sensitivity, specificity, and reproducibility.
Q3: Where can the test be used?
A: It can be used in district hospitals, primary health centres, and even mobile clinics because it runs on the portable Truenat platform.
Q4: Why is this test important for India?
A: It is affordable and accessible, unlike expensive imported tests. It can reach millions of women who currently have no screening access.
Q5: Does this replace HPV vaccination?
A: No. Vaccination prevents new HPV infections in young girls. Screening detects existing infections in older women. Both are needed to eliminate cervical cancer.